<table id="t4" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4: Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction [see <linkhtml href="#S12.3">Clinical Pharmacology (12.3)</linkhtml>]</caption>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="50%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Concomitant Drug Class:<br/> Drug Name</th>
<th stylecode="Rrule">Effect on Concentration of Rilpivirine or Concomitant Drug </th>
<th stylecode="Rrule">Clinical Comment</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">↑ = increase, ↓ = decrease, ↔ = no change<br/>
</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-Antiviral Agents: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">didanosine<footnote id="t4fn1">The interaction between EDURANT and the drug was evaluated in a clinical study. All other drug-drug interactions shown are predicted.</footnote>
<footnote id="t4fn2">This interaction study has been performed with a dose higher than the recommended dose for EDURANT assessing the maximal effect on the co-administered drug. The dosing recommendation is applicable to the recommended dose of EDURANT 25 mg once daily.</footnote>
</td>
<td stylecode="Rrule">↔ rilpivirine<br/>↔ didanosine</td>
<td stylecode="Rrule">No dose adjustment is required when EDURANT is co-administered with didanosine. Didanosine is to be administered on an empty stomach and at least two hours before or at least four hours after EDURANT (which should be administered with a meal).</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-Antiviral Agents: Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">NNRTI<br/> (delavirdine)</td>
<td stylecode="Rrule">↑ rilpivirine<br/>↔ delavirdine</td>
<td stylecode="Rrule">It is not recommended to co-administer EDURANT with delavirdine and other NNRTIs.<br/>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Other NNRTIs<br/>(efavirenz, etravirine, nevirapine)</td>
<td stylecode="Rrule">↓ rilpivirine<br/>↔ other NNRTIs</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-Antiviral Agents: Protease Inhibitors (PIs)-Boosted (i.e., with co-administration of low-dose ritonavir) or Unboosted (i.e., without co-administration of low-dose ritonavir)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">darunavir/ritonavir<footnoteref idref="t4fn1"></footnoteref>
<footnoteref idref="t4fn2"></footnoteref>
</td>
<td stylecode="Rrule ">↑ rilpivirine<br/>↔ boosted darunavir</td>
<td stylecode="Rrule ">Concomitant use of EDURANT with darunavir/ritonavir may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A enzymes). No dose adjustment is required when EDURANT is co-administered with darunavir/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">lopinavir/ritonavir<footnoteref idref="t4fn1"></footnoteref>
<footnoteref idref="t4fn2"></footnoteref>
</td>
<td stylecode="Rrule ">↑ rilpivirine<br/>↔ boosted lopinavir</td>
<td stylecode="Rrule ">Concomitant use of EDURANT with lopinavir/ritonavir may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A enzymes). No dose adjustment is required when EDURANT is co-administered with lopinavir/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">other boosted PIs (atazanavir/ritonavir, fosamprenavir/ritonavir, saquinavir/ritonavir, tipranavir/ritonavir)</td>
<td stylecode="Rrule ">↑ rilpivirine<br/>↔ boosted PI</td>
<td stylecode="Rrule ">Concomitant use of EDURANT with boosted PIs may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A enzymes). EDURANT is not expected to affect the plasma concentrations of co-administered PIs.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">unboosted PIs (atazanavir, fosamprenavir, indinavir, nelfinavir)</td>
<td stylecode="Rrule ">↑ rilpivirine<br/>↔ unboosted PI</td>
<td stylecode="Rrule ">Concomitant use of EDURANT with unboosted PIs may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A enzymes). EDURANT is not expected to affect the plasma concentrations of co-administered PIs.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Other Agents</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antacids:</content>
<br/>antacids (e.g., aluminum or magnesium hydroxide, calcium carbonate)</td>
<td stylecode="Rrule ">↔ rilpivirine<br/> (antacids taken at least 2 hours before or at least 4 hours after rilpivirine)<br/>
<br/>
</td>
<td stylecode="Rrule ">The combination of EDURANT and antacids should be used with caution as co-administration may cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). Antacids should only be administered either at least 2 hours before or at least 4 hours after EDURANT.<br/>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">↓ rilpivirine<br/> (concomitant intake)</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterials:</content>
<br/>rifabutin<footnoteref idref="t4fn1"></footnoteref>
</td>
<td stylecode="Rrule">↓ rilpivirine</td>
<td stylecode="Rrule">Concomitant use of EDURANT with rifabutin may cause a decrease in the plasma concentrations of rilpivirine (induction of CYP3A enzymes). Throughout co-administration of EDURANT with rifabutin, the EDURANT dose should be increased from 25 mg once daily to 50 mg once daily. When rifabutin co-administration is stopped, the EDURANT dose should be decreased to 25 mg once daily.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Azole Antifungal Agents</content>:<br/>fluconazole<br/>itraconazole<br/>ketoconazole<footnoteref idref="t4fn1"></footnoteref>
<footnoteref idref="t4fn2"></footnoteref>
<br/>posaconazole<br/>voriconazole</td>
<td stylecode="Rrule ">↑ rilpivirine<br/>↓ ketoconazole</td>
<td stylecode="Rrule ">Concomitant use of EDURANT with azole antifungal agents may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A enzymes). No rilpivirine dose adjustment is required when EDURANT is co-administered with azole antifungal agents. Clinically monitor for breakthrough fungal infections when azole antifungals are co-administered with EDURANT.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">H<sub>2</sub>-Receptor Antagonists</content>:<br/>cimetidine<br/>famotidine<footnoteref idref="t4fn1"></footnoteref>
<footnoteref idref="t4fn2"></footnoteref>
<br/>nizatidine<br/>ranitidine</td>
<td stylecode="Rrule ">↔ rilpivirine<br/> (famotidine taken 12 hours before rilpivirine or 4 hours after rilpivirine)</td>
<td stylecode="Rrule ">The combination of EDURANT and H<sub>2</sub>-receptor antagonists should be used with caution as co-administration may cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). H<sub>2</sub>-receptor antagonists should only be administered at least 12 hours before or at least 4 hours after EDURANT.<br/>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">↓ rilpivirine<br/> (famotidine taken 2 hours before rilpivirine)</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Macrolide or ketolide antibiotics</content>:<br/>clarithromycin<br/>erythromycin<br/>telithromycin</td>
<td stylecode="Rrule ">↑ rilpivirine<br/>↔ clarithromycin<br/>↔ erythromycin<br/>↔ telithromycin</td>
<td stylecode="Rrule ">Concomitant use of EDURANT with clarithromycin, erythromycin or telithromycin may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A enzymes). Where possible, alternatives such as azithromycin should be considered.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Narcotic Analgesics</content>:<br/>methadone<footnoteref idref="t4fn1"></footnoteref>
</td>
<td stylecode="Rrule ">↓ R(-) methadone<br/>↓ S(+) methadone</td>
<td stylecode="Rrule ">No dose adjustments are required when initiating co-administration of methadone with EDURANT. However, clinical monitoring is recommended as methadone maintenance therapy may need to be adjusted in some patients.</td>
</tr>
</tbody>
</table>